Truncated Thioredoxin: Physiological Functions and Mechanism

Antioxidants and Redox Signaling

Volumn 6, Issue 1, 2004, Pages 53-61

  Pekkari, Klas ^a   Holmgren, Arne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYSTEINE; CYTOKINE; GAMMA INTERFERON; GLYCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 2; MITOGENIC AGENT; PROLINE; PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE); PROTEIN TRX80; PROTEIN TRX84; RECOMBINANT PROTEIN; THIOREDOXIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGEN EXPRESSION; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EOSINOPHIL; HUMAN; HUMAN CELL; MONOCYTE; MONONUCLEAR CELL; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MOTIF; PROTEIN SECRETION; REVIEW; TH1 CELL;

EID: 0346340023     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/152308604771978345     Document Type: Review

References (76)

1. Abdiu A, Nakamura H, Sahaf B, Yodoi J, Holmgren A, and Rosén A. Thioredoxin blood level increases after severe burn injury. Antioxid Redox Signal 2: 707-716, 2000.
2. Balcewicz-Sablinska MK, Wollman EE, Gorti R, and Silberstein DS. Human eosinophil cytotoxicity-enhancing factor. II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor. J Immunol 147: 2170-2174, 1991.
3. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-681, 1996.
4. Barral AM, Källström R, Sander B, and Rosén A. Thioredoxin, thioredoxin reductase and tumour necrosis factor-alpha expression in melanoma cells: correlation to resistance against cytotoxic attack. Melanoma Res 10: 331-343, 2000.
5. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16: 3459-3466, 1996.
6. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, Caselli G, Pagliei S, Romines B, Wilshire JA, Mengozzi M, Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A, Herzenberg LA, and Ghezzi P. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 189: 1783-1789, 1999.
7. Constant SL and Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15: 297-322, 1997.
8. Dessein AJ, Lenzi HL, Bina JC, Carvalho EM, Weiser WY, Andrade ZA, and David JR. Modulation of eosinophil cytotoxicity by blood mononuclear cells from healthy subjects and patients with chronic schistosomiasis mansoni. Cell Immunol 85: 100-113, 1984.
9. Dessein AJ, Lee TH, Elsas P, Ravalese D, Silberstein D, David JR, Austen KF, and Lewis RA. Enhancement by monokines of leukotriene generation by human eosinophils and neutrophils stimulated with calcium ionophore A23187. J Immunology 136: 3829-3838, 1986.
10. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, and Gregory CD. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392: 505-509, 1998.
11. Di Trapani G, Perkins A, and Clarke F. Production and secretion of thioredoxin from transformed human trophoblast cells. Mol Hum Reprod 4: 369-375, 1998.
12. Eklund H, Gleason FK, and Holmgren A. Structural and functional relations among thioredoxins of different species. Proteins 11: 13-28, 1991.
13. Elsas MI, Dessein AJ, and Elsas PX. Selection of U937 histiocytic lymphoma cells highly responsive to phorbol ester-induced differentiation using monoclonal antibody to the eosinophil cytotoxicity-enhancing factor. Blood 75: 2427-2433, 1990.
14. Elsas PX, Elsas MI, and Dessein AJ. Eosinophil cytotoxicity enhancing factor: purification, characterization and immunocytochemical localization on the monocyte surface. Eur J Immunol 20: 143-1151, 1990.
15. Farina AR, Tacconelli A, Cappabianca L, Masciulli MP, Holmgren A, Beckett GJ, Gulino A, and Mackay AR. Thioredoxin alters the matrix metalloproteinase/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion. Eur J Biochem 268: 405-413, 2001.
16. Germann T and Rude E. Interleukin-12. Int Arch Allergy Immunol 108: 103-112, 1995.
17. Gregory CD, Devitt A, and Moffatt O. Roles of ICAM-3 and CD14 in the recognition and phagocytosis of apoptotic cells by macrophages. Biochem Soc Trans 26: 644-649, 1998.
18. Grewal IS and Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111-135, 1998.
19. Grippo JF, Holmgren A, and Pratt WB. Proof that the endogenous, heat-stable glucocorticoid receptor-activating factor is thioredoxin. J Biol Chem 260: 93-97, 1985.
20. Harper R, Wu K, Chang MM, Yoneda K, Pan R, Reddy SP, and Wu R. Activation of nuclear factor-kappa B transcriptional activity in airway epithelial cells by thioredoxin but not by N-acetyl-cysteine and glutathione. Am J Respir Cell Mol Biol 25: 178-185, 2001.
21. Heidenreich S. Monocyte CD14: a multifunctional receptor engaged in apoptosis from both sides. J Leukoc Biol 65: 737-743, 1999.
22. Higashikubo A, Tanaka N, Noda N, Maeda I, Yagi K, Mizoguchi T, and Nanri H. Increase in thioredoxin activity of intestinal epithelial cells mediated by oxidative stress. Biol Pharm Bull 22: 900-903, 1999.
23. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94: 3633-3638, 1997.
24. Hirota K, Murata M, Sachi Y, Nakamura H, Takeuchi J, Mori K, and Yodoi J. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274: 27891-27897, 1999.
25. Hirota K, Matsui M, Murata M, Takashima Y, Cheng FS, Itoh T, Fukuda K, and Yodoi J. Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-kappaB, AP-1, and CREB activation in HEK293 cells. Biochem Biophys Res Commun 274: 177-182, 2000.
26. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J Biol Chem 254: 9627-9632, 1979.
27. Holmgren A. Thioredoxin. Annu Rev Biochem 54: 237-271, 1985.
28. Holmgren A and Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 252: 199-208, 1995.
29. Holmgren A and Luthman M. Tissue distribution and subcellular localization of bovine thioredoxin determined by radioimmunoassay. Biochemistry 17: 4071-4077, 1978.
30. Holmgren A, Söderberg BO, Eklund H, and Brändén CI. Three-dimensional structure of Escherichia coli thioredoxin-S2 to 2.8 A resolution. Proc Natl Acad Sci U S A 72: 2305-2309, 1975.
31. Hoshi Y, Tanooka H, Miyazaki K, and Wakasugi H. Induction of thioredoxin in human lymphocytes with low-dose ionizing radiation. Biochim Biophys Acta 1359: 65-70, 1997.
32. Iwai T, Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H, and Yodoi J. Expression of adult T-cell leukaemia-derived factor, a human thioredoxin homologue, in the human ovary throughout the menstrual cycle. Virchows Arch A Pathol Anat Histopathol 420: 213-217, 1992.
33. Lee SM, Suen Y, Qian J, Knoppel E, and Cairo MS. The regulation and biological activity of interleukin 12. Leuk Lymphoma 29: 427-438, 1998.
34. Lenzi HL, Mednis AD, and Dessein AJ. Activation of human eosinophils by monokines and lymphokines: source and biochemical characteristics of the eosinophil cytotoxicity-enhancing activity produced by blood mononuclear cells. Cell Immunol 94: 333-346, 1985.
35. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104: 365-372, 2001.
36. Lippoldt A, Padilla CA, Gerst H, Andbjer B, Richter E, Holmgren E, and Fuxe K. Localization of thioredoxin in the rat brain and functional implications. J Neurosci 15: 6747-6756, 1995.
37. Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, Umesono K, Makino I, and Tanaka H. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 98: 2469-2477, 1996.
38. Makino Y, Yoshikawa N, Okamoto K, Hirota K, Yodoi J, Makino I, and Tanaka H. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem 274: 3182-3188, 1999.
39. Martin JL. Thioredoxin - a fold for all reasons. Structure 3: 245-250, 1995.
40. Maruyama T, Sachi Y, Furuke K, Kitaoka Y, Kanzaki H, Yoshimura Y, and Yodoi J. Induction of thioredoxin, a redox-active protein, by ovarian steroid hormones during growth and differentiation of endometrial stromal cells in vitro. Endocrinology 140: 365-372, 1999.
41. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K, and Yodoi J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 69: 2091-2097, 1992.
42. Nakamura H, De Rosa S, Roederer M, Anderson MT, Dubs JG, Yodoi J, Holmgren A, and Herzenberg LA. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 8: 603-611, 1996.
43. Nakamura H, Nakamura K, and Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 15: 351-369, 1997.
44. Nakamura H, Vaage J, Valen G, Padilla CA, Björnstedt M, and Holmgren A. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic Biol Med 24: 1176-1186, 1998.
45. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, and Herzenberg LA. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci U S A 98: 2688-2693, 2001.
46. Nakashima T, Sumida Y, Yoh T, Kakisaka Y, Nakajima Y, Ishikawa H, Mitsuyoshi H, Kashima K, Nakamura J, and Yodoi J. Thioredoxin levels in the sera of untreated viral hepatitis patients and those treated with glycyrrhizin or ursodeoxycholic acid. Antioxid Redox Signal 2: 687-694, 2000.
47. Newman GW, Balcewicz-Sablinska MK, Guarnaccia JR, Remold HG, and Silberstein DS. Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1. J Exp Med 180: 359-363, 1994.
48. Pekkari K, Gurunath R, Arner ES, and Holmgren A. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 275: 37474-37480, 2000.
49. Pekkari K, Avila-Carino J, Bengtsson A, Gurunath R, Scheynius A, and Holmgren A. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood 97: 3184-3190, 2001.
50. Pekkari K, Avila-Carino J, Gurunath R, Bengtsson A, Scheynius A, and Holmgren A. Truncated thioredoxin (Trx80) exerts unique mitogenic cytokine effects via a mechanism independent of thiol oxido-reductase activity. FEBS Lett 539: 143-148, 2003.
51. Rosén A, Lundman P, Carlsson M, Bhavani K, Srinivasa BR, Kjellstrom G, Nilsson K, and Holmgren A. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol 7: 625-633, 1995.
52. Rubartelli A, Bajetto A, Allavena G, Wollman E, and Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 267: 24161-24164, 1992.
53. Sahaf B, and Rosén A. Secretion of 10-kDa and 12-kDa thioredoxin species from blood monocytes and transformed leukocytes. Antioxid Redox Signal 2: 717-726, 2000.
54. Sahaf B, Söderberg A, Spyrou G, Barral AM, Pekkari K, Holmgren A, and Rosén A. Thioredoxin expression and localization in human cell lines: detection of full-length and truncated species. Exp Cell Res 236: 181-192, 1997.
55. Saito I, Shimuta M, Terauchi K, Tsubota K, Yodoi J, and Miyasaka N. Increased expression of human thioredoxin/adult T cell leukemia-derived factor in Sjogren's syndrome. Arthritis Rheum 39: 773-782, 1996.
56. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
57. Schenk H, Klein M, Erdbrugger W, Droge W, and Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci U S A 91: 1672-1676, 1994.
58. Schenk H, Vogt M, Dröge W, and Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine expression. J Immunol 156: 765-771, 1996.
59. Schönbeck U and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58: 4-43, 2001.
60. Silberstein DS, Dessein AJ, Elsas PP, Fontaine B, and David JR. Characterization of a factor from the U937 cell line that enhances the toxicity of human eosinophils to Schistosoma mansoni larvae. J Immunol 138: 3042-3050, 1987.
61. Silberstein DS, Ali MH, Baker SL, and David JR. Human eosinophil cytotoxicity-enhancing factor. Purification, physical characteristics, and partial amino acid sequence of an active polypeptide. J Immunol 143: 979-983, 1989.
62. Silberstein DS, McDonough S, Minkoff MS, and Balcewicz-Sablinska MK. Human eosinophil cytotoxicity-enhancing factor. Eosinophil-stimulating and dithiol reductase activities of biosynthetic (recombinant) species with COOH-terminal deletions. J Biol Chem 268: 9138-9142, 1993.
63. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, Paaakko P, Holmgren A, and Kinnula VL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001.
64. Sornasse T, Larenas PV, Davis KA, de Vries JE, and Yssel H. Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level. J Exp Med 184: 473-483, 1996
65. Spellberg B and Edwards JE. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 32: 76-102, 2001.
66. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H, Sakamoto Y, Okanoue T, Kashima K, Nakamura H, and Yodoi J. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 33: 616-622, 2000.
67. Tagaya Y, Okada M, Sugie K, Kasahara T, Kondo N, Hamuro J, Matsushima K, Dinarello CA, and Yodoi J. IL-2 receptor(p55)/Tac-inducing factor. Purification and characterization of adult T cell leukemia-derived factor. J Immunol 140: 2614-2620, 1988.
68. Tagaya Y, Maeda Y, Mitsui A, Kondo N, Matsui H, Hamuro J, Brown N, Arai K, Yokota T, Wakasugi H, et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 8: 757-764, 1989.
69. Tagaya Y, Wakasugi H, Masutani H, Nakamura H, Iwata S, Mitsui A, Fujii S, Wakasugi N, Tursz T, and Yodoi J. Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction. Mol Immunol 27: 1279-1289, 1990.
70. Takagi Y, Gon Y, Todaka T, Nozaki K, Nishiyama A, Sono H, Hashimoto N, Kikuchi H, and Yodoi J. Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries. Lab Invest 78: 957-966, 1998.
71. Takashima Y, Hirota K, Nakamura H, Nakamura T, Akiyama K, Cheng FS, Maeda M, and Yodoi J. Differential expression of glutaredoxin and thioredoxin during monocytic differentiation. Immunol Lett 68: 397-401, 1999.
72. Ueda S, Nakamura H, Masutani H, Sasada T, Yonehara S, Takabayashi A, Yamaoka Y, and Yodoi J. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J Immunol 161: 6689-6695, 1998.
73. Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J, and Tursz T. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci U S A 87: 8282-8286, 1990.
74. Wollman EE, Kahan A, and Fradelizi D. Detection of membrane associated thioredoxin on human cell lines. Biochem Biophys Res Commun 230: 602-606, 1997.
75. Yamauchi A, Masutani H, Tagaya Y, Wakasugi N, Mitsui A, Nakamura H, Inamoto T, Ozawa K, and Yodoi J. Lymphocyte transformation and thiol compounds; the role of ADF/thioredoxin as an endogenous reducing agent. Mol Immunol 29: 263-270, 1992.
76. Yoshida S, Katoh T, Tetsuka T, Uno K, Matsui N, and Okamoto T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J Immunol 163: 351-358,1999.